Crinetics Pharmaceuticals (CRNX) risk factors, FY2024 10-K

Risks related to our limited operating history, financial position and capital requirements

1. 01We have a limited operating history, have incurred significant operating losses since our inception and expect to continue to incur losses. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it
2. 02We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could lead us to delay, limit, reduce, abandon or terminate our product development programs, commercialization efforts or other operations
3. 03our ability to participate in any future equity offering by Radionetics

Risks related to the discovery and development and regulatory approval of our product candidates

1. 04We have two product candidates in clinical development, and all of our other research programs are still in the preclinical or discovery stage. If we are unable to successfully develop any product candidates or experience significant delays in doing so, our business will be materially harmed
2. 05maintaining and growing an organization of scientists and businesspeople who can develop our products and technology
3. 06We cannot assure you that we will be able to successfully discover and develop any product candidates
4. 07For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful, and the failure of any our product candidates could have a material adverse effect on our business, financial condition and results of operations
5. 08delays in our clinical trials resulting from external factors including global conflicts or health epidemics
6. 09Use of our product candidates could be associated with side effects or adverse events, which could severely harm our business, reputation, prospects, operating results and financial condition
7. 10Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates
8. 11studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program
9. 12the FDA or other comparable foreign regulatory authorities may experience disruptions to the review or approval process
10. 13which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate
11. 14We have conducted, and continue to conduct, clinical trials for our current product candidates outside of the United States, and we may do so for our other product candidates. However, conducting trials outside of the United States exposes us to additional risks, which could materially harm our business
12. 15interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism
13. 16Changes in U.S. and international trade policies, particularly with respect to China, Europe and India may adversely impact our business and operating results
14. 17Initial, interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data

Risks related to commercialization of our product candidates

1. 18injunctions or the imposition of civil or criminal penalties
2. 19The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
3. 20Disruptions at the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business
4. 21The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, health care payors and others in the medical community
5. 22the public perception regarding any products we may develop
6. 23The numbers of patients suffering from the rare endocrine diseases and endocrine-related tumors that we target is small and have not been established with precision. If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer
7. 24We have sought and may continue to seek to enter into collaborations, licenses and other similar arrangements of our product and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships
8. 25Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks related to our reliance on third parties

1. 26We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates
2. 27Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
3. 28Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks related to our business operations and industry

1. 29We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
2. 30We may encounter difficulties in managing our growth and expanding our operations successfully
3. 31We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer
4. 32We are subject to various foreign, federal and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition
5. 33Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could have a material adverse effect on our business, financial condition or results of operations
6. 34facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA
7. 35Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set
8. 36Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. It is unclear how any such challenges and the healthcare reform measures of the current administration, or any future presidential administration, will impact the ACA or our business
9. 37If product liability or state consumer protection act lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
10. 38a decline in our stock price
11. 39We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business
12. 40Our employees and independent contractors, including principal investigators, CROs, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
13. 41We may not realize any benefits from our relationship with Radionetics
14. 42The increasing use of social media and artificial intelligence-based platforms presents new risks and challenges

Risks related to our intellectual property

1. 43Our success depends on our ability to protect our intellectual property and our proprietary technologies, and if we are unable to protect our intellectual property and technologies, our business will suffer
2. 44countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates
3. 45If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be material and adversely affected
4. 46We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
5. 47Intellectual property rights do not necessarily address all potential threats to our competitive advantage
6. 48Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
7. 49require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology
8. 50Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
9. 51Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
10. 52Changes in U.S. patent law, or laws in other countries or jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
11. 53We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
12. 54Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
13. 55If we do not obtain patent term extension for our product candidates, our business may be materially harmed
14. 56We may not be able to protect our intellectual property rights throughout the world
15. 57Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
16. 58If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
17. 59If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
18. 60We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks related to our common stock

1. 61An active, liquid and orderly market for our common stock may not be maintained
2. 62The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses
3. 63intellectual property, product liability or other litigation by or against us
4. 64Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval
5. 65We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
6. 66Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
7. 67Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
8. 68Our ability to use net operating loss carryforwards and other tax attributes may be limited
9. 69Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
10. 70We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
11. 71Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
12. 72the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners
13. 73We and any of our third-party manufacturers and suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly
14. 74Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs
15. 75Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
16. 76Unfavorable global economic conditions could adversely affect our business, financial condition and stock price
17. 77If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
18. 78The increasing focus and evolving expectations with respect to on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results
19. 79Changes in tax laws may impact our financial condition and results of operations
20. 80We could be subject to securities class action litigation